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Figure 1:  Flowchart shows enrollment of readers into the study. 
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Figure 2. Plots show correlation between (a) cancer detection rates, (b) recall rate, and (c) positive 
predictive value in real life and the PERFORMS tests sets. 
Figure 2A: Graph shows correlation between cancer detection in real life and in the PERFORMS test sets. 
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Figure 2. Plots show correlation between (a) cancer detection rates, (b) recall rate, and (c) positive 
predictive value in real life and the PERFORMS tests sets. 
Figure 2B: Graph shows correlation between recall rate in real life and in PERFORMS test sets. 
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Figure 2. Plots show correlation between (a) cancer detection rates, (b) recall rate, and (c) positive 
predictive value in real life and the PERFORMS tests sets. 
Figure 2C: Graph shows correlation between positive predictive value (PPV) in real life and PPV in the 
PERFORMS test sets. 
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1 Relationship Between Mammography Readers Real-life Performance and Performance in a Test-
2 set Based Assessment Scheme in a National Breast Screening Programme
3
4 Original Research 
5
6 Abbreviations: 
7 ANOVA = analysis of variance, BSIS = Breast Screening Information System, NHSBSP = National Health 
8 Service Breast Screening Programme, PACS = Picture Archiving and Communication System, 
9 PERFORMS = Personal Performance in Mammographic Screening, PPV = positive predictive value, ROC 




14 -Readers’ Breast cancer Screening Information System (BSIS) real-life performance significantly 
15 correlated with PERFORMS test for cancer detection rates (r = 0.179, P < .001), recall rates (r = 0.146, 
16 P = .002), and positive predictive value (r = 0.263, P < .001). 
17 -Outliers in PERFORMS had significantly poorer real-life cancer detection rate and PPV of recall 
18 compared to the non-outlier group of readers.
19 -The PERFORMS tests has the potential to predict readers’ performance and can be used to determine 
20 potential reading problems. 
21  
22 Summary statement:
23 The use of a test set based assessment scheme (PERFORMS) in a breast screening program has the 
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33 Purpose: To compare an individual’s Personal Performance in Mammographic Screening (PERFORMS) 
34 score with their Breast Screening Information System (BSIS) real-life performance data and determine 
35 which parameters in the PERFORMS scheme offer the best reflection of BSIS real-life performance 
36 metrics.  
37 Methods:  In this retrospective study, the BSIS real-life performance metrics of individual readers (n 
38 = 452) in the NHS Breast Screening Programme (NHSBSP) in England were compared with 
39 performance in the test-set based assessment scheme over a 3-year period from 2013-2016.  Cancer 
40 detection rate, recall rate, and positive predictive value (PPV) were calculated for each reader, for 
41 both real-life screening and the PERFORMS test.  For each metric, real-life and test-set versions were 
42 compared using a Pearson correlation.
43 The real-life cancer detection rate, recall rate, and PPV of outliers were compared against other 
44 readers (non-outliers) using ANOVA.
45 Results: BSIS real-life cancer detection rates, recall rates, and PPV showed positive correlations with 
46 the equivalent PERFORMS measures (P < 0.001, P = 0.002, P < 0.001, respectively).  The mean real-life 
47 cancer detection rate (CDR) of PERFORMS outliers was 7.2 per 1000 women screened and was 
48 significantly lower than other readers (non-outliers) where the real-life cancer detection rate was 7.9 
49 (P = 0.002). The mean real-life screening PPV of PERFORMS outliers was 0.14% and was significantly 
50 lower than the non-outlier group who had a mean PPV of 0.17% (P = 0.006). 
51 Conclusions: The use of test-set based assessment schemes in a breast screening program has the 
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57 There has been considerable interest in recent years for the assessment of performance of healthcare 
58 personnel.  Individuals providing care have a duty to demonstrate satisfactory performance, forming 
59 part of appraisal and revalidation.  Measuring individual performance has the potential to improve 
60 the quality of services offered, inform the public, determine potential problems, and provide 
61 supportive further training (1). 
62 Breast radiology in the United Kingdom (UK), particularly in the context of the National Health Service 
63 Breast Screening Programme (NHSBSP), has always had its performance heavily audited as part of the 
64 quality assurance process which is integral to the service.  Data on each of the screening centers has 
65 been collected and published since programme inception in 1988 (2). In addition, to provide a measure 
66 of individual performance, a test set based system called PERFORMS (Personal Performance in 
67 Mammographic Screening) has been running for over 30 years (3).  Participants whose performance 
68 in the scheme is below a minimum acceptable standard (statistically significantly lower than that of 
69 the main body of readers) are flagged up as ‘outliers’ and further action is taken, such as reviewing 
70 practice, offering suggestions, or further training. 
71 There has been criticism that test-set based performance schemes may suffer from a “laboratory 
72 effect” and not be a true reflection of real-life performance. Many studies demonstrate that 
73 experimental conditions can affect human behaviour (4). Test sets, by their very nature, are heavily 
74 enriched with cancer cases and the reader knows that any decisions they make in the test environment 
75 will have no patient impact and so reading behaviour may be altered (5).
76 Recently, the UK Breast Screening Information System (BSIS), which provides national and local 
77 performance statistics for the NHSBSP, has produced individual real-life performance data over rolling 
78 three-year periods. The aim of this study is to compare an individual’s PERFORMS test set scores with 
79 their real-life performance data and determine which parameters in the PERFORMS scheme offer the 
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80 best reflection of real-life performance metrics.  In addition, this study aims to determine whether the 
81 'outlier' status in the PERFORMS scheme is a true predictor of poor performance in real life. 
82
83 Materials and Methods
84 Study Design
85 All 706 readers who interpret screening mammograms for the NHSBSP in England and who take part 
86 in the PERFORMS self-assessment test were invited to participate in the study. Ethics approval was 
87 waived, following discussion with the local Research and Development Team as this retrospective 
88 comparison was considered to represent an audit of current practice. The study was carried out in 
89 accordance with the local Information System Security Policy, Data Protection Policy, and associated 
90 Codes of Practice and Guidelines, with participants giving informed consent for their performance 
91 data to be accessed. 
92 A total of 582 readers consented for their real-life data to be accessed for the study. Real-life data 
93 were obtained from BSIS for the three-year period 2013-2016. Study participants had to have 
94 completed at least five rounds of the PERFORMS self-assessment scheme (i.e. 5 sets of 60 cases) 
95 within 36 months of the BSIS real-life screening data period.  The NHSBSP requires readers to 
96 interpret 5000 mammograms each year, but at least 1500 of these have to be as a first reader (3).   
97 Consequently, participants had to read at least 1500 screening cases per year as a first reader, and 
98 no less than a total of 4500 cases as a first reader over the three-year period of the study to be 
99 included.  In additional, participants were excluded if their real-life data could not be identified or 
100 matched with their PERFORMS data.  Consequently, a total of 452 readers were available for the 
101 comparison.  The flow chart in Figure 1, outlines the recruitment process and exclusion criteria.
102
Page 11 of 24































































103 PERFORMS Image Assessment
104 The PERFORMS scheme involves the circulation of test sets of 60 challenging cases, consisting of 
105 normal, benign, and abnormal mammograms. The test sets are heavily enriched with biopsy proven 
106 cancers (typically around 35%), with radiological features of masses, calcifications, asymmetries and 
107 distortions.  Benign and normal cases are either biopsy proven or have at least three years of 
108 mammographic follow-up.   Cases are chosen by the scheme organisers in conjunction with a 
109 national panel of ten expert breast radiologists with more than 20 years of experience working in the 
110 NHSBSP from a pool contributed by all UK screening centres.  PERFORMS is currently undertaken by 
111 over 800 readers in the UK (6) as part of the quality assurance for the NHSBSP (7). Readers in the UK 
112 screening program include board certified radiologists, radiographers, or breast clinicians (doctors 
113 who are not radiologists working in the field of breast diagnosis). Non-radiologists typically make up 
114 half the readers in the UK programme and are trained to Masters level or equivalent and, along with 
115 the radiologists, have to undertake the reading of a minimum of 5000 mammograms per year (8).
116 The test-set images are uploaded to the Picture Archiving and Communication System (PACS) at each 
117 screening centre where they can be viewed.  Readers’ findings are recorded on a password 
118 protected website and participants receive immediate feedback on each case at the end of the set, 
119 compared to pathology and an opinion derived from a national panel of  experts, who provide a 
120 commentary on the radiological appearances of the cancers and the appropriateness of recall for the 
121 normal and benign cases.  Once completed by all readers, comprehensive performance statistics are 
122 produced providing an individual with a comparison with their peers nationally.  Data is produced on 
123 correct recall for further assessment, correct return to normal screening, cancer detection rate, and 
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129 The NHSBSP uses double reading as standard and so the performance data produced primarily 
130 focuses on the opinion of the individual as a first reader.  In many centers, the second reader is not 
131 blinded to the opinion of the first reader and so the first read is the only truly unbiased read.  The 
132 data extracted included a unique reader code, screening center name, number of cases read as first 
133 reader, number of recalled cases, cancers detected as first reader, as well as rate of discrepant 
134 cancers per year (defined as cancers missed by the first reader that where subsequently identified 
135 by the second reader).  Comparative results from the PERFORMS tests sets were obtained from the 
136 PERFORMS data base which consisted of reader ID, screening center name, correct and incorrect 
137 recall, correct return to screening, and missed cancer rates.
138 Measures of sensitivity were selected to be analogous in real-life screening and in test-set based 
139 performance.  In real-life screening, the cancer detection rate was calculated as the number of 
140 women in whom cancer was detected per 1000 women screened.  For PERFORMS, the cancer 
141 detection rate was calculated as the percentage of cancers detected out of the total number of cases 
142 in the test set.  Positive predictive value was calculated as the total number of cancers detected out 
143 of the total number of cases recalled, for both real-life screening performance and the test-set based 
144 performance; the number of “true positives” divided by the number of “true positives” plus “false 
145 positives”.  The real-life BSIS data cannot provide a true specificity measure or a negative predictive 
146 value (NPV).  Due to the development of cancers between screening rounds (interval cancers), 
147 determining which cases are true and false negatives will not become apparent for many years.  
148 Consequently, in real-life screening the recall rate is used as a proxy for specificity.  Recall rate was 
149 calculated as the total number of cases recalled out of the total number of cases read, for both the 
150 real-life screening and test-set based performance measures.  
151
152
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154 Cancer detection rate, recall rate, and positive predictive value (PPV) measures were calculated from 
155 the PERFORMS data and from the BSIS real-life data, yielding two values per reader for each metric: 
156 one real-life screening-based value and one test-set based value.  For each of these measures, a 
157 Pearson correlation between the PERFORMS test-set data and BSIS real-life screening data was 
158 examined.  Further analysis assessed whether those readers whose performance on the PERFORMS 
159 test was deemed to be below the minimum acceptable standard (the outliers) had significantly 
160 poorer performance on the BSIS real-life screening measures.  PERFORMS outliers are readers whose 
161 test performance falls more than one and a half times the inter-quartile range below the 25th 
162 percentile in terms of either cancer detection rate in the PERFORMS test set or the area under the 
163 curve of the receiver operating characteristic (ROC) analysis of their test set performance (or both). 
164 For the purposes of this study, any reader who had been an outlier on any of the PERFORMS test-
165 sets included in three-year period, were allocated into an ‘Outliers’ group.  The real-life cancer 
166 detection rates, recall rates, and PPVs of PERFORMS outliers were then compared against those of 
167 other readers using analysis of variance (ANOVA).  The α-level for statistical significance was set at 
168 .05 for all analyses. Statistical calculations were performed using the IBM SPSS Statistics (version 
169 23.0) statistical software (SPSS Inc., Chicago, IL). 
170
171 Results
172 Participant Performance Overview
173 In total, 452 participants (238 board certified radiologists, 193 radiographer readers, and 21 breast 
174 clinicians) consented and were eligible to take part in the study. The mean cancer detection rate 
175 from the BSIS real-life data was 7.79 per 1000 women screened (0.78%) with a mean recall rate of 
176 5.29%.  Each PERFORMS test set of 60 cases is heavily enriched with cancers; the number of cancer 
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177 cases varied between 34 and 38 for the PERFORMS sets included in this study.  The mean cancer 
178 detection rate in the PERFORMS test sets was 22.86% with a mean recall rate of 37.49%.  A summary 
179 of the BSIS real-life and PERFORMS performance measures for the participants is given in Table 1.
180
181 Test Measures Assessed from BSIS Real-life and PERFORMS Correlate 
182 BSIS real-life cancer detection rates, recall rates, and PPVs showed significant positive correlations 
183 with the equivalent PERFORMS measures (n = 452).  Readers with a higher cancer detection rate in 
184 real-life tended to have a higher cancer detection rate in PERFORMS (Pearson’s Correlation: r = 
185 0.179, P < .001, two tails; Figure 2A).  Readers with a higher recall rate in real-life screening tended 
186 to have a higher recall rate in PERFORMS (Pearson’s Correlation: r =  0.146, P = .002, two tails; Figure 
187 2B).  PPV, the probability that a patient recalled following screening mammography has a confirmed 
188 breast malignancy, reflects a combination of cancer detection rate and recall rate.  Readers with a 
189 higher PPV in real-life screening tended to have a higher PPV in PERFORMS (Pearson’s Correlation: r 
190 = 0.263, P < .001, two tails; Figure 2C).  It is noted that, as PPV is affected by the prevalence of the 
191 disease, PPV in the test-set data was considerably higher than in the real-life data, reflecting the 
192 difference in the prevalence of cancers in the two data-sets.
193
194 Comparison of Outliers and Nonoutliers
195 Outliers in the PERFORMS scheme were found to have significantly lower performance than other 
196 readers in real-life screening in terms of cancer detection rate and PPV, but did not differ 
197 significantly in terms of recall rate (Table 2).  The mean BSIS real-life screening cancer detection rate 
198 of PERFORMS outliers was 7.2 per 1000 women screened and was significantly lower than other 
199 readers (non-outliers) where the cancer detection rate was 7.9 per 1000 women screened (ANOVA 
200 F(1, 450) = 9.78, p = .002, ω = .014) (Figure 3A).  The mean BSIS real-life screening recall rate of 
201 PERFORMS outliers was 5.5% and was not different from that of other readers who had a mean of 
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202 5·3% (ANOVA F(1, 450) = 0.67, P = .415, ω = .003) (Figure 3B).  The mean BSIS real-life screening PPV 
203 of PERFORMS outliers was 0.14% and was significantly lower than the non-outlier group who had a 
204 mean PPV of 0.17% (ANOVA F(1, 450) = 7.75, P = .006, ω = .012) (Figure 3C). 
205
206 Discussion
207 This study was designed to determine if performance in the PERFORMS test set scheme reflected 
208 BSIS real-life performance.  Test set performance demonstrated significant positive correlations with 
209 the BSIS real-life performance metrics produced by the UK screening programme, i.e. cancer 
210 detection rate(r = 0.179, P < .001), recall rate(r =  0.146, P = .002), PPV(r = 0.263, P < .001) all showed 
211 strong correlations  For breast cancer screening to be successful, cancer detection rates need to be 
212 optimized, but at the same time recall rates need to be kept as low as possible to avoid false positive 
213 interpretation and recalls.  There will always be a trade-off between recalling women for further 
214 investigation and detecting cancers, which is reflected in the PPV.  Recall rates act as a proxy for 
215 specificity in real-life screening, due to the difficulty in identifying true negatives and false negatives 
216 at the time of reading.  However, recall rates are not a perfect measure of specificity.  Recall rates 
217 need to be interpreted in conjunction with cancer detection – both low and high recall rates would 
218 be acceptable in the context of high cancer detection, whereas in isolation extreme recall rates may 
219 raise concerns about a reader’s performance.
220 Correlation between BSIS real-life recall rates and PERFORMS correct recall rates was the least strong 
221 of the performance metrics, although it did reach statistical significance (r =  0.146, P = .002).  One of 
222 the criticisms of test sets is that reading behaviour may be altered.  This weaker correlation is probably 
223 not surprising as it has previously demonstrated that recall rates are particularly prone to this 
224 ‘laboratory’ effect, as readers know that flagging a patient for recall will have no impact on patient 
225 care (4).
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226 Previous studies comparing test-set and real-life performance have shown consistently positive 
227 relationships, albeit weak in some instances (9-11). One of the strengths of this study is that is has 
228 been possible to compare real-life performance data with results from a test-set scheme in a large 
229 group of readers.  Soh et al reported reasonable levels (P<.01) of agreement between actual clinical 
230 reporting and test set conditions, although increased sensitivity was seen under test set conditions 
231 (11).  This study of 452 participants demonstrated much stronger associations than a previous smaller 
232 study of 40 readers from one UK region taking part in the same PERFORMS scheme in 2005 and 2006 
233 (10).  PPV of recall demonstrated the strongest correlation between BSIS real-life and PERFORMS data 
234 for all participants.  PPV is one of the most useful measures of performance (12). 
235 Real-life performance data is often considered the reference standard. However, the accuracy of 
236 sensitivity and specificity of real-life breast cancer screening data is problematic (13).  Reader 
237 sensitivity, which is defined as the proportion of patients with breast cancer reported as positive, is 
238 not known for several years until interval cancer data becomes available and even then real life data 
239 may not be updated to reflect this.  Due to this unavoidable time lag, the opportunity to introduce 
240 timely interventions to improve performance is lost. Similarly, when measuring specificity as the 
241 proportion of disease-free patients reported as negative, a truly negative mammogram will not be 
242 apparent until after the next screening round at the earliest.  One of the advantages of test sets like 
243 PERFORMS is that normal, benign, and malignant cases with known, biopsy proven outcomes and 
244 appropriate follow up can be selected for inclusion, providing potentially more accurate performance 
245 metrics.  For instance, when choosing cases for PERFORMS, a normal case will only be included if the 
246 mammogram at the next screening round three years later is also normal. 
247 One of the key functions of measuring performance is to identify potential problems at the earliest 
248 opportunity to allow interventions to change practice.  Real life data is by its very nature retrospective.  
249 Cancer detection rates of around 7-8 per 1000 women screened mean that an individual reader is 
250 exposed to relatively few cancers each year. Consequently, it can be difficult to identify poor 
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251 performance because of the statistical instability from the relatively small number of cancer cases, 
252 similar problems are encountered when measuring performance in NHSBSP screening centres with 
253 the smallest number of clients (14).  BSIS audit data are combined over a three-year period to improve 
254 the statistical robustness of the performance measures, but even so many years of poor performance 
255 may occur before this becomes apparent through clinical audit, resulting in potential harm to the 
256 screening population.  For many years the PERFORMS scheme has flagged up poor performance 
257 outliers where metrics have deviated significantly from the mean. Individuals and the regional quality 
258 assurance office are notified so that corrective measured can be instigated such as reviewing practice 
259 or further training.    PERFORMS has the potential to identify under performance at a much earlier 
260 stage than real-life data, perhaps even before a reader takes part in the screening programme as part 
261 of an end of training or pre-employment assessment.   If test sets are to be used in this way, then it is 
262 crucial that the results are validated against real-life data.   In this study, being a poor performance 
263 outlier in PERFORMS was able to predict poor real-life performance with outliers have significantly 
264 poorer real-life cancer detection rate and PPV of recall compared to the non-outlier group of readThis 
265 study does have limitations. Nearly 20% of PERFORMS participants (124 readers) declined to have 
266 their data used and so this has to be considered a potential source of bias.   Further work is needed to 
267 understand if this group had any particular characteristics.  
268 In conclusion, there are significant correlations between real-life readers’ performance in a breast 
269 screening programme and their performance on metrics generated from a test-set based assessment 
270 scheme such as PERFORMS.  Readers’ positive predictive value of recall in real-life screening and the 
271 test-sets showed the strongest correlations.  The use of test-set based assessment schemes has the 
272 potential to predict and identify potential poor performance outliers in real-life screening, enabling 
273 corrective measures to be implemented in a timely fashion. 
274
275 Funding:.
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0.13, 0.19 6.82, 8.76 4.17, 6.18 68.89, 78.17 21.67, 24.03 33.96, 40.28
Note –– A total of 452 radiologists were assessed for real-life performance and PERFORMS. PPV = positive predictive 
value; CI = confidence interval; PERFORMS = Personal Performance in Mammographic Screening.
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Table 2: Summary of Real-life and PERFORMS Performance Measures Based on Whether or not Readers were 
an “Outlier” in the PERFORMS Test Sets
 Real-life performance metrics
Number of cancers 
detected per 1000 
women screened  (n)
Recall rate (%) Positive predictive value (%)
PERFORMS Outlier Status (2013-2016)
Values
Non-
outlier Outlier Non-outlier Outlier Non-outlier Outlier
Mean ± 
standard 
deviation 7.9 ± 1.5 7.2 ± 1.5 5.3 ± 1.8 5.5 ± 1.8 0.17 ± 0.06 0.14 + 0.04
95% 
confidence 

















percentile 6.9, 8.8 6.6, 8.2 4.2, 6.2 4.3, 6.1 0.13, 0.19 0.11, 0.17
P value 0.002 0.415 0.006
Note –– There were a total of 396 non-outliers and 56 outliers. PPV = positive predictive value; CI = confidence interval; 
PERFORMS = Personal Performance in Mammographic Screening.
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Figure 1:  Flowchart shows enrolment of readers into the study.
Figure 2. Plots show correlation between (a) cancer detection rates, (b) recall rate, and (c) positive predictive 
value in real life and the PERFORMS tests sets.
Figure 2A: Graph shows correlation between cancer detection in real life and in the PERFORMS test sets.
Figure 2B: Graph shows correlation between recall rate in real life and in PERFORMS test sets.
Figure 2C: Graph shows correlation between positive predictive value (PPV) in real life and PPV in the 
PERFORMS test sets. 
Figure 3: A total of 396 non-outliers and 56 outliers were assessed for their cancer detection rates per 1000 
women, recall rates, and positive predictive value (PPV). Box-and-whisker plots show (a) real-life cancer 
detection rates, (b) real-life recall rates, and (c) real-life PPVs based on whether or not readers were an “outlier” 
in the PERFORMS test sets. The 95% confidence limits are shown on each plot. 
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